Back to top
more

Oncolytics Biotech (ONCY)

(Delayed Data from NSDQ)

$1.04 USD

1.04
4,685

+0.01 (0.97%)

Updated Apr 19, 2024 09:45 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

New Strong Buy Stocks for January 18th

by Zacks Equity Research

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Sanghamitra Saha headshot

2 Sector ETFs Hovering Around a 52-Week High

by Sanghamitra Saha

We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.

What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

by Zacks Equity Research

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech

by Zacks Equity Research

Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Oncolytics Biotech (ONCY) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Oncolytics Biotech (ONCY) has been struggling lately, but the selling pressure may be coming to an end soon.

Here's Why Oncolytics Biotech Inc. (ONCY) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Sanghamitra Saha headshot

5 Stocks With Rising P/E Are Good Buys

by Sanghamitra Saha

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

Down 23.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Oncolytics Biotech Inc. (ONCY)

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Here's Why Oncolytics Biotech Inc. (ONCY) is Poised for a Turnaround After Losing 19.6% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Oncolytics Biotech (ONCY) Enters Overbought Territory

by Zacks Equity Research

Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Tirthankar Chakraborty headshot

New Strong Buy Stocks For May 28th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:

Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.

Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat

by Zacks Equity Research

Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.

Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA

by Zacks Equity Research

Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech

Tirthankar Chakraborty headshot

Coronavirus Infects Wall Street: Stocks to Gain & Lose

by Tirthankar Chakraborty

While travel-related stocks were hit hard on concerns over coronavirus, experimental vaccine companies rallied.

Will Oncolytics Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Oncolytics.